Hexarelin對缺血再灌注心肌的保護(hù)作用及機制研究
[Abstract]:Myocardial ischemia-reperfusion injury refers to the aggravation of myocardial injury after the recovery of blood supply and oxygen supply in ischemic myocardial tissue, which is mainly manifested as follows: 1) oxidative stress injury, 2) calcium overload, 3) aggravation of inflammatory reaction, 4) apoptosis of cardiomyocytes, 2) calcium overload, 3) aggravation of inflammatory reaction, 4) apoptosis of cardiomyocytes, and 4) apoptosis of cardiomyocytes. 5) Vascular endothelial dysfunction, 6) no reflow, 6) no reflow. Hexarelin is a synthetic growth hormone releasing peptide, which is involved in myocardial ischemia-reperfusion and myocardial infarction. Experimental studies such as myocardial fibrosis and atherosclerosis have been confirmed to have definite cardioprotective effects. Hexarelin has cardiovascular effects by binding to growth hormone secretin receptor 1a (growth hormone secretagogue receptor 1a. GHSR 1a) and cardiac specific CD36 receptor. At present, the effect of hexarelin on myocardial ischemia-reperfusion injury in vivo is not very clear, and its mechanism has not been clarified. The purpose of this study was as follows: 1) to study the protective effect of hexarelin on ischemia-reperfusion myocardium by establishing a rat model of myocardial ischemia-reperfusion, 2) to study the relationship between the effect of hexarelin on myocardial ischemia-reperfusion injury and IL-1 signaling pathway. 3) to determine whether the effect of hexarelin on IL-1 signaling pathway is related to the activation of cardiac specific GHSR 1a receptor. We selected 6-week-old male SD rats to establish myocardial ischemia-reperfusion model by ligating the left anterior descending branch of coronary artery to induce myocardial ischemia and reperfusion. After modeling, hexarelin,ghrelin or saline were given to each group for 7 days, then cardiac systolic function was evaluated by echocardiography, and oxidative stress injury was evaluated by malondialdehyde (malondialdehyde,MDA). The number of viable myocardium was evaluated by tissue section analysis, and the effect of hexarelin on myocardial ischemia-reperfusion injury was evaluated and compared with that of ghrelin. Then we detected the expression of IL-1 signaling pathway in myocardial tissue of rats in each experimental group by RT-PCR and Western blot, in order to evaluate the effect of hexarelin on IL-1 signaling pathway in ischemia-reperfusion myocardium. Furthermore, the activation of GHSR 1a receptor was blocked by GHSR 1a receptor antagonist, and the effect of IL-1 signaling pathway was observed by Western blot in order to explore the role of cardiac specific GHSR 1a receptor in this process. Our study found that hexarelin can improve cardiac systolic dysfunction, reduce the production of oxygen free radicals and increase the number of viable myocardium after myocardial ischemia-reperfusion injury, and its effect is better than that of ghrelin, at the same dose. Especially in inhibiting the production of oxygen free radicals and improving ejection fraction. At the same time, we found that hexarelin could induce the expression of IL-1 signaling pathway in ischemia-reperfusion myocardium, and the effect of hexarelin on IL-1 signaling pathway could be partially neutralized by GHSR 1a receptor antagonist. Based on the above experimental results, we draw the following conclusions: 1) hexarelin can effectively improve myocardial ischemia-reperfusion injury, such as inhibiting the production of oxygen free radicals, increasing the number of viable myocardium and improving cardiac contractile function; 2) the protective effect of hexarelin on ischemia-reperfusion myocardium is realized by inhibiting the activation of IL-1 signaling pathway, and 3) the effect of hexarelin on IL-1 signaling pathway is the result of hexarelin activating cardiac specific GHSR1a receptor. In this paper, the protective effect of hexarelin on ischemia-reperfusion myocardium and its mechanism were discussed, which provided a new direction and train of thought for the treatment of myocardial ischemia-reperfusion injury.
【學(xué)位授予單位】:山東大學(xué)
【學(xué)位級別】:博士
【學(xué)位授予年份】:2017
【分類號】:R54
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 吳有華,任江華,曹茂銀,邵玲;淺低溫對麻醉兔急性缺血再灌注心肌作用的研究[J];中國老年學(xué)雜志;2005年04期
2 楊天德;劉橋義;;納洛酮抗心肌缺血再灌注損傷的研究進(jìn)展[J];國外醫(yī)學(xué).麻醉學(xué)與復(fù)蘇分冊;1993年01期
3 王粵,朱科明;鎂對缺血再灌注心肌的保護(hù)[J];中國急救醫(yī)學(xué);1999年02期
4 魏宏;何并文;;藥物后處理對缺血再灌注心肌保護(hù)的研究進(jìn)展[J];臨床合理用藥雜志;2009年11期
5 趙淑敏;劉勝;楊宏光;孔祥玉;宋成軍;劉永平;;黃芩莖葉總黃酮預(yù)處理對缺血再灌注心肌脂質(zhì)過氧化損傷的保護(hù)作用[J];解剖學(xué)雜志;2006年04期
6 張君平;杜友愛;郭益民;劉重斌;余立群;;鎂對大鼠離體缺血再灌注心肌的作用[J];溫州醫(yī)學(xué)院學(xué)報;2008年02期
7 劉冬云;劉坤申;;大鼠缺血再灌注心肌Toll樣受體4與腫瘤壞死因子-α和核因子-κB的表達(dá)及其關(guān)系[J];中國全科醫(yī)學(xué);2009年06期
8 魏育濤;陳新忠;董念國;朱佳龍;譚峰;;遠(yuǎn)距缺血后適應(yīng)對缺血再灌注心肌的保護(hù)作用[J];臨床心血管病雜志;2011年04期
9 陳君;邊云飛;郝小燕;肖傳實;;不同濃度脂聯(lián)素通過減輕氧化應(yīng)激損傷保護(hù)缺血再灌注心肌[J];中國動脈硬化雜志;2010年11期
10 宋秀媛,姜波,王尊哲,陳維寧,李寧,高爾;普洛托品對缺血再灌注心肌的保護(hù)作用[J];中國病理生理雜志;2000年10期
相關(guān)會議論文 前10條
1 李俊明;馬業(yè)新;程芳洲;黃俊;;過氧化物酶體增殖物激活受體α在實驗性大鼠缺血再灌注心肌中的表達(dá)[A];中華醫(yī)學(xué)會心血管病分會第八次全國心血管病學(xué)術(shù)會議匯編[C];2004年
2 韓珂;魏振宇;史舉彤;孫鵬飛;;缺血再灌注心肌炎性細(xì)胞因子的表達(dá)對心肌間質(zhì)的影響[A];中華醫(yī)學(xué)會第七次全國胸心血管外科學(xué)術(shù)會議暨2007中華醫(yī)學(xué)會胸心血管外科青年醫(yī)師論壇論文集心血管外科分冊[C];2007年
3 富青;熊凡;李萍;丁成縈;曾慶云;王喬;田宗文;;Hsp70對缺血再灌注心肌的保護(hù)作用的研究[A];解剖學(xué)雜志——中國解剖學(xué)會2002年年會文摘匯編[C];2002年
4 周玉平;;丹參酮ⅡA對缺血再灌注心肌EPOR表達(dá)的影響及其機制初探[A];首屆江西省科協(xié)學(xué)術(shù)年會江西省中醫(yī)藥學(xué)術(shù)發(fā)展論壇論文集[C];2010年
5 李西寬;茍偉;劉俊田;鄧秀玲;孫曉明;邊衛(wèi)國;;3,6-[二甲氨基]-二苯并碘雜六環(huán)葡萄糖酸鹽對大鼠缺血再灌注心肌的保護(hù)作用[A];中國藥理學(xué)會第八次全國代表大會論文摘要集(第二部分)[C];2002年
6 楊萍;李華;章永南;吳艷;孫惠華;涂秋英;李紅;;缺血再灌注心肌EPOR的表達(dá)調(diào)控及丹參酮ⅡA的干預(yù)作用[A];江西省中西醫(yī)結(jié)合學(xué)會第九次活血化瘀學(xué)術(shù)研討會活血化瘀臨床應(yīng)用新進(jìn)展培訓(xùn)班論文集[C];2011年
7 李海青;石剛剛;;鈣拮抗劑對大鼠缺血再灌注心肌Egr-1的作用[A];第九屆全國心血管藥理學(xué)術(shù)會議論文集[C];2007年
8 李西寬;茍偉;劉俊田;鄧秀玲;孫曉明;邊衛(wèi)國;;3,6-[二甲氨基]-二苯并碘雜六環(huán)葡萄糖酸鹽對大鼠缺血再灌注心肌的保護(hù)作用[A];中國藥理學(xué)會第八次全國代表大會暨全國藥理學(xué)術(shù)會議論文摘要匯編[C];2002年
9 王峰;梁貴友;湯全;劉達(dá)興;徐剛;張建;李劍;;HIF-1α在成年大鼠心肌細(xì)胞缺血再灌注心肌胰島素抵抗中的表達(dá)及意義[A];2012貴州省醫(yī)學(xué)會胸心血管外科年會論文集[C];2012年
10 張博;范謙;高峰;;胰島素對模擬缺血再灌注心肌細(xì)胞的作用[A];中國生理學(xué)會第21屆全國代表大會暨學(xué)術(shù)會議論文摘要匯編[C];2002年
相關(guān)博士學(xué)位論文 前4條
1 黃健男;Hexarelin對缺血再灌注心肌的保護(hù)作用及機制研究[D];山東大學(xué);2017年
2 王卉;硒與丹參酮II_A并用對兔心肌缺血再灌注的保護(hù)作用[D];遼寧中醫(yī)藥大學(xué);2008年
3 劉景詩;冠脈轉(zhuǎn)染Nrf2基因?qū)Υ笫笕毖俟嘧⑿募〉谋Wo(hù)作用及機制的研究[D];中南大學(xué);2010年
4 錢洪津;c-Jun氨基末端激酶(JNK)信號轉(zhuǎn)導(dǎo)通路對缺血再灌注心肌作用的實驗研究[D];第一軍醫(yī)大學(xué);2006年
相關(guān)碩士學(xué)位論文 前3條
1 李永慧;缺血后處理對大鼠在體缺血再灌注心肌縫隙連接蛋白43的影響[D];山西醫(yī)科大學(xué);2008年
2 吳有華;淺低溫對麻醉兔急性缺血再灌注心肌作用及機制的研究[D];武漢大學(xué);2005年
3 葛毅萍;NECA對兔急性缺血再灌注心肌的保護(hù)作用及其對血管內(nèi)皮功能的影響[D];青島大學(xué);2008年
,本文編號:2490599
本文鏈接:http://sikaile.net/yixuelunwen/xxg/2490599.html